Managing Crohn’s Disease: Guidelines and Treatment Options

Crohn’s disease is a type of inflammatory bowel disease that can affect any part of the digestive tract. To manage this condition, the National Institute for Health and Care Excellence (NICE) has published guidelines that provide recommendations for inducing and maintaining remission, as well as treating complications. One of the most important steps in managing Crohn’s disease is to advise patients to quit smoking, as this can worsen the condition. Additionally, some medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and the combined oral contraceptive pill, may increase the risk of relapse, although the evidence is not conclusive.

To induce remission, glucocorticoids are often used, either orally, topically, or intravenously. Budesonide is an alternative for some patients. Enteral feeding with an elemental diet may also be used, especially in young children or when there are concerns about the side effects of steroids. Second-line treatments for inducing remission include 5-ASA drugs like mesalazine, as well as azathioprine or mercaptopurine, which may be used in combination with other medications. Methotrexate is another option. Infliximab is useful for refractory disease and fistulating Crohn’s, and patients may continue on azathioprine or methotrexate.

To maintain remission, stopping smoking is a priority, and azathioprine or mercaptopurine is used first-line. TPMT activity should be assessed before starting these medications. Methotrexate is used second-line. Surgery may be necessary for around 80% of patients with Crohn’s disease, depending on the location and severity of the disease. Complications of Crohn’s disease include small bowel cancer, colorectal cancer, and osteoporosis. Perianal fistulae and abscesses require specific treatments, such as oral metronidazole, anti-TNF agents like infliximab, or a draining seton. By following these guidelines and treatment options, patients with Crohn’s disease can better manage their condition and improve their quality of life.

Hepatocellular carcinoma is primarily caused by hepatitis B worldwide, while in Europe, hepatitis C is the most common cause.

Hepatocellular carcinoma (HCC) is a type of cancer that ranks as the third most common cause of cancer worldwide. The leading cause of HCC globally is chronic hepatitis B, while chronic hepatitis C is the most common cause in Europe. The primary risk factor for developing HCC is liver cirrhosis, which can result from various factors such as hepatitis B and C, alcohol, haemochromatosis, and primary biliary cirrhosis. Other risk factors include alpha-1 antitrypsin deficiency, hereditary tyrosinosis, glycogen storage disease, aflatoxin, certain drugs, porphyria cutanea tarda, male sex, diabetes mellitus, and metabolic syndrome.

HCC tends to present late, and patients may exhibit features of liver cirrhosis or failure such as jaundice, ascites, RUQ pain, hepatomegaly, pruritus, and splenomegaly. In some cases, decompensation may occur in patients with chronic liver disease. Raised AFP levels are also common. Screening with ultrasound and alpha-fetoprotein may be necessary for high-risk groups, including patients with liver cirrhosis secondary to hepatitis B and C or haemochromatosis, and men with liver cirrhosis secondary to alcohol.

Management options for early-stage HCC include surgical resection, liver transplantation, radiofrequency ablation, transarterial chemoembolisation, and sorafenib, a multikinase inhibitor. It is important to note that Wilson’s disease is an exception to the typical causes of liver cirrhosis and HCC.

Treatment and Diagnosis of Acute Pancreatitis

Acute pancreatitis can lead to systemic inflammatory response syndrome and multiple organ dysfunction syndromes. The mainstay of treatment is supportive measures such as fluid resuscitation and oxygen supplementation. Abdominal ultrasound can be useful to identify gallstones as the cause of pancreatitis, but fluid resuscitation takes priority. IV antibiotics are not indicated unless complications occur. Enteral feeding is preferred over nil by mouth, and parenteral feeding should be considered if enteral feeding is not tolerated. Urgent CT of the abdomen is not necessary in the acute stage unless complications are suspected. However, for severe pancreatitis, contrast-enhanced CT may be indicated four days after initial symptoms to assess for complications.

Microcytic Anaemia: Causes and Considerations

Microcytic anaemia is a condition characterized by small red blood cells and low haemoglobin levels. There are several possible causes of microcytic anaemia, including iron-deficiency anaemia, thalassaemia, congenital sideroblastic anaemia, and lead poisoning. It is important to note that while anaemia of chronic disease can also present with microcytosis, it typically appears as a normocytic, normochromic picture.

In some cases, a normal haemoglobin level may be observed alongside microcytosis. This can be a red flag for polycythaemia rubra vera, which can cause iron-deficiency secondary to bleeding. Additionally, new onset microcytic anaemia in elderly patients should be investigated promptly to rule out underlying malignancy. It is worth noting that in beta-thalassaemia minor, the microcytosis may be disproportionate to the anaemia.

Overall, understanding the potential causes and considerations of microcytic anaemia is crucial for proper diagnosis and treatment.

For a mild-moderate flare of distal ulcerative colitis, the recommended first-line treatment is rectal aminosalicylates. This is particularly effective if the inflammation is limited to the rectum. If rectal aminosalicylates are not effective, oral aminosalicylates may be used in combination with or instead of the topical treatment. However, if the patient has contraindications or intolerances to aminosalicylates, topical or oral steroids may be preferred. Intravenous steroids are typically reserved for severe flares of colitis with symptoms such as frequent bloody stools, systemic upset, anemia, or elevated inflammatory markers.

Ulcerative colitis can be managed through inducing and maintaining remission. The severity of the condition is classified as mild, moderate, or severe based on the number of stools and presence of systemic upset. Treatment for mild-to-moderate cases of proctitis involves using topical aminosalicylate, while proctosigmoiditis and left-sided ulcerative colitis may require a combination of oral and topical medications. Extensive disease may require a high-dose oral aminosalicylate and topical treatment. Severe colitis should be treated in a hospital with intravenous steroids or ciclosporin. Maintaining remission can involve using a low maintenance dose of an oral aminosalicylate or oral azathioprine/mercaptopurine. Methotrexate is not recommended, but probiotics may prevent relapse in mild to moderate cases.

CA 19-9 and Pancreatic Cancer

Understanding Tumour Markers

Tumour markers are substances that can be found in the blood, urine, or tissues of people with cancer. They are often used to help diagnose and monitor cancer, as well as to determine the effectiveness of treatment. Tumour markers can be divided into different categories, including monoclonal antibodies against carbohydrate or glycoprotein tumour antigens, tumour antigens, enzymes, and hormones.

Monoclonal antibodies are used to target specific tumour antigens, which are proteins or other molecules that are found on the surface of cancer cells. Some common tumour markers include CA 125 for ovarian cancer, CA 19-9 for pancreatic cancer, and CA 15-3 for breast cancer. However, it is important to note that tumour markers usually have a low specificity, meaning that they can also be found in people without cancer.

Tumour antigens are proteins that are produced by cancer cells and can be detected in the blood or tissues of people with cancer. Some examples of tumour antigens include prostate specific antigen (PSA) for prostatic carcinoma, alpha-feto protein (AFP) for hepatocellular carcinoma and teratoma, and carcinoembryonic antigen (CEA) for colorectal cancer.

Enzymes and hormones can also be used as tumour markers. For example, alkaline phosphatase and neurone specific enolase are enzymes that can be elevated in people with cancer, while hormones such as calcitonin and ADH can be used to detect certain types of cancer.

In summary, tumour markers are an important tool in the diagnosis and monitoring of cancer. However, they should be used in conjunction with other diagnostic tests and imaging studies, as they are not always specific to cancer and can also be elevated in people without cancer.

Common Gastrointestinal Conditions and Their Symptoms

Gastrointestinal conditions can present with a variety of symptoms, making diagnosis challenging. Here are some common conditions and their associated symptoms:

Oesophagitis: Inflammation of the oesophagus can cause asymptomatic, epigastric or substernal burning pain, dysphagia, and increased discomfort when lying down or straining. It is often caused by gastro-oesophageal reflux disease, alcohol, non-steroidal anti-inflammatory drugs, bisphosphonates, smoking, or Candida albicans infection. Treatment involves eliminating precipitating causes and using proton-pump inhibitors.

Oesophageal carcinoma: This type of cancer typically presents with worsening dysphagia, weight loss, heartburn, and changes in voice due to compression of the recurrent laryngeal nerve.

Gastric carcinoma: Symptoms of gastric cancer are often non-specific and include weight loss, anorexia, and fatigue. Heartburn and indigestion are rare.

Duodenal ulcer: Pain associated with duodenal ulcers is typically improved with eating and severe enough to impact nutritional intake, leading to weight loss. Patients at high risk of gastric ulceration due to medication use may be prescribed a proton-pump inhibitor.

Pancreatic carcinoma: This type of cancer often presents very late with painless jaundice and weight loss, which are not seen in the presented case.

Primary biliary cholangitis is a chronic liver disease that primarily affects middle-aged women. It is characterized by the destruction of small bile ducts in the liver, leading to cholestasis and liver damage. The disease is diagnosed through blood tests that measure levels of specific antibodies and liver enzymes, which are highly specific to the condition. Ursodeoxycholic acid is the preferred treatment for slowing disease progression and improving symptoms, while cholestyramine can be used to alleviate itching but does not affect disease progression. In cases of decompensated liver disease, such as when bilirubin levels exceed 100, liver transplantation may be an option. Although recurrence in the graft can occur, it is typically not a significant issue. While fat-soluble vitamins can be supplemented, they are not a primary treatment option.

Primary Biliary Cholangitis: A Chronic Liver Disorder

Primary biliary cholangitis, previously known as primary biliary cirrhosis, is a chronic liver disorder that is commonly observed in middle-aged women. The exact cause of this condition is not yet fully understood, but it is believed to be an autoimmune disease. The disease is characterized by the progressive damage of interlobular bile ducts due to chronic inflammation, leading to cholestasis and eventually cirrhosis. The most common symptom of primary biliary cholangitis is itching in middle-aged women.

This condition is often associated with other autoimmune diseases such as Sjogren’s syndrome, rheumatoid arthritis, systemic sclerosis, and thyroid disease. Early symptoms of primary biliary cholangitis may be asymptomatic or may include fatigue, pruritus, and cholestatic jaundice. Late symptoms may progress to liver failure. Diagnosis of primary biliary cholangitis involves immunology tests such as anti-mitochondrial antibodies (AMA) M2 subtype and smooth muscle antibodies, as well as imaging tests to exclude an extrahepatic biliary obstruction.

The first-line treatment for primary biliary cholangitis is ursodeoxycholic acid, which slows down the progression of the disease and improves symptoms. Cholestyramine is used to alleviate pruritus, and fat-soluble vitamin supplementation is recommended. In severe cases, liver transplantation may be necessary, especially if bilirubin levels exceed 100. However, recurrence in the graft can occur, but it is not usually a problem. Complications of primary biliary cholangitis include cirrhosis, portal hypertension, ascites, variceal hemorrhage, osteomalacia, osteoporosis, and an increased risk of hepatocellular carcinoma.

Understanding Complications of ERCP: Pancreatitis, Cholangitis, and More

ERCP (endoscopic retrograde cholangiopancreatography) is a common procedure used to diagnose and treat conditions of the bile ducts and pancreas. However, like any medical procedure, it carries risks and potential complications. One such complication is pancreatitis, which can present with non-specific symptoms but may be accompanied by hypocalcaemia. Immediate management includes confirming the diagnosis and severity of pancreatitis, intravenous fluid resuscitation, oxygen, and adequate analgesia. Another potential complication is ascending cholangitis, which can present with fever, jaundice, and abdominal pain. Biliary perforation is a serious but infrequent complication that is usually recognized during the procedure, while intestinal perforation is not an expected complication. A reaction to contrast would have occurred during the procedure. It is important to understand these potential complications and their symptoms in order to provide prompt and appropriate management.

Elevated serum amylase levels are not always indicative of acute pancreatitis, as they can also be seen in cases of small bowel obstruction. In this scenario, the patient is experiencing abdominal pain, vomiting, and a lack of bowel movements or gas, which are all typical symptoms of small bowel obstruction. The fact that the patient has a history of abdominal surgery further supports this diagnosis, despite the misleading blood test results. Acute cholecystitis, on the other hand, presents with different symptoms such as fever, right upper quadrant pain, and systemic distress, and does not typically cause elevated amylase levels. Acute pancreatitis may also be considered as a differential diagnosis, but it is not associated with a lack of bowel movements or gas, and previous bowel surgery is not a risk factor. Ascending cholangitis and large bowel obstruction can also be ruled out based on the patient’s symptoms and test results.

Small bowel obstruction occurs when the small intestines are blocked, preventing the passage of food, fluids, and gas. The most common cause of this condition is adhesions, which can develop after previous surgeries, followed by hernias. Symptoms of small bowel obstruction include diffuse, central abdominal pain, nausea and vomiting (often bilious), constipation, and abdominal distension. Tinkling bowel sounds may also be present in early stages of obstruction. Abdominal x-ray is typically the first-line imaging for suspected small bowel obstruction, showing distended small bowel loops with fluid levels. CT is more sensitive and considered the definitive investigation, particularly in early obstruction. Management involves initial steps such as NBM, IV fluids, and nasogastric tube with free drainage. Some patients may respond to conservative management, but others may require surgery.